From the Doctor
Dr. Manuel Hidalgo, MD, PhD, Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology, is an internationally respected oncologist whose groundbreaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer. He is also Co-Director of the Pancreas and Liver Institute, and Co-Director of the Pancreatic Cancer Research Program, at the Beth Israel Deaconess Medical Center (BIDMC). His research interests have centered in translational and clinical research in anticancer drug development with a particular emphasis in pancreatic cancer.
“We have led the early clinical development of more than 50 new anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer. Our most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalizes medicine in PDAC. About 15 years ago we initiated the development of patient derived xenograft models of pancreas cancer as a platform for translational studies in this disease. Using a well-characterized PDX models we identified nab-paclitaxel activity in pancreas cancer, a work than paved the way for clinical studies that eventually led to the approval of the drug. More recently we have identified demcizumab and palbociclib that are now in early clinical development as well. I am also using this approach in a multicenter study named AVATAR that aims to use mouse model for personalize medicine approaches. Our immediate goal now is to incorporate immune treatment approaches both in preclinical models and in clinical studies in pancreas cancer.”